Zacks Investment Research downgraded shares of Galapagos NV (NASDAQ:GLPG) from a hold rating to a sell rating in a report released on Monday morning.

According to Zacks, “Galapagos NV is a biotechnology company. The Company’s operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. “

A number of other equities research analysts have also recently commented on the stock. Janney Montgomery Scott upgraded shares of Galapagos NV from a sell rating to a neutral rating in a research report on Friday, July 7th. They noted that the move was a valuation call. Nomura cut their price objective on shares of Galapagos NV from $108.00 to $121.00 and set a buy rating for the company in a research report on Thursday, June 22nd. Cowen and Company restated a buy rating on shares of Galapagos NV in a research report on Wednesday, June 21st. BidaskClub upgraded shares of Galapagos NV from a sell rating to a hold rating in a research report on Thursday, August 17th. Finally, BTIG Research restated a buy rating and set a $98.00 price objective on shares of Galapagos NV in a research report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. Galapagos NV presently has a consensus rating of Buy and an average target price of $108.14.

Shares of Galapagos NV (GLPG) traded down 0.62% during trading on Monday, hitting $101.96. 23,959 shares of the company’s stock were exchanged. Galapagos NV has a 12-month low of $57.16 and a 12-month high of $103.97.

ILLEGAL ACTIVITY WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/06/galapagos-nv-glpg-downgraded-by-zacks-investment-research-to-sell.html.

A number of institutional investors have recently added to or reduced their stakes in the stock. Federated Investors Inc. PA increased its position in Galapagos NV by 36.8% during the second quarter. Federated Investors Inc. PA now owns 1,364,600 shares of the biotechnology company’s stock worth $104,419,000 after purchasing an additional 366,800 shares during the last quarter. EcoR1 Capital LLC increased its position in Galapagos NV by 5.0% during the second quarter. EcoR1 Capital LLC now owns 578,505 shares of the biotechnology company’s stock worth $44,267,000 after purchasing an additional 27,464 shares during the last quarter. Renaissance Technologies LLC increased its position in Galapagos NV by 49.5% during the second quarter. Renaissance Technologies LLC now owns 465,300 shares of the biotechnology company’s stock worth $35,605,000 after purchasing an additional 154,100 shares during the last quarter. Wellington Management Group LLP increased its position in Galapagos NV by 9.5% during the first quarter. Wellington Management Group LLP now owns 458,088 shares of the biotechnology company’s stock worth $39,483,000 after purchasing an additional 39,729 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Galapagos NV by 0.6% during the second quarter. Goldman Sachs Group Inc. now owns 202,173 shares of the biotechnology company’s stock worth $15,471,000 after purchasing an additional 1,235 shares during the last quarter. Hedge funds and other institutional investors own 23.62% of the company’s stock.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Get a free copy of the Zacks research report on Galapagos NV (GLPG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Stock Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related stocks with our FREE daily email newsletter.